Evidence map›Paper›PMID 33607086›Full record

ArticleBiophysical journal2021

Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction.

Wenpeng Cao, Chuqiao Dong, Seonghan Kim, Decheng Hou, Wanbo Tai, Lanying Du, Wonpil Im, X Frank Zhang

Open access · bronzeAbstract read
In one paragraph

Article in Biophysical journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 138 citations in OpenAlex.

  1. Article
  2. Drugs against broad-spectrum of coronaviruses.Frontiers in immunology · 2026
    Review
  3. Understanding Viral-Glycocalyx Interactions Using Brush-Linked to Cross-Linked Models.Langmuir : the ACS journal of surfaces and colloids · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Biophysical investigation of interactions between SARS-CoV-2 spike protein and neuropilin-1.Protein science : a publication of the Protein Society · 2023
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Wenpeng CaoDepartment of Bioengineering.
Chuqiao DongDepartment of Mechanical Engineering and Mechanics.
Seonghan KimDepartments of Biological Sciences, Chemistry, and Computer Science and Engineering, Lehigh University, Bethlehem, Pennsylvania.
Decheng HouDepartment of Bioengineering.
Wanbo TaiLindsley F. Kimball Research Institute, New York Blood Center, New York, New York.
Lanying DuLindsley F. Kimball Research Institute, New York Blood Center, New York, New York.
Wonpil ImDepartment of Bioengineering; Departments of Biological Sciences, Chemistry, and Computer Science and Engineering, Lehigh University, Bethlehem, Pennsylvania. Electronic address: woi216@lehigh.edu.
X Frank ZhangDepartment of Bioengineering; Department of Mechanical Engineering and Mechanics. Electronic address: xiz310@lehigh.edu.
Lehigh University · USNew York Blood Center · USBioengineering Center · RU

Funding

Novel nanobodies to prevent and treat SARS-CoV-2 and other pathogenic human coronavirusesR01AI157975 · NIAID · NEW YORK BLOOD CENTER · PI DU, LANYING, LI, FANG · 2020 to 2025
$3.9M
Development of Computational Toolset for Structural Systems PharmacologyR01GM126140 · NIGMS · LEHIGH UNIVERSITY · PI IM, WONPIL · 2018 to 2020
$1.1M
Biomechanics of TIM Protein-Mediated Ebola Virus-Host Cell AdhesionR15AI133634 · NIAID · LEHIGH UNIVERSITY · PI JAGOTA, ANAND, ZHANG, XIAOHUI · 2018 to 2018
$435k
NIAID NIH HHS R01 AI157975NIAID NIH HHS R15 AI133634NIGMS NIH HHS R01 GM126140
6 · The paper itself

Abstract

The current COVID-19 pandemic has led to a devastating impact across the world. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (the virus causing COVID-19) is known to use the receptor-binding domain (RBD) at viral surface spike (S) protein to interact with the angiotensin-converting enzyme 2 (ACE2) receptor expressed on many human cell types. The RBD-ACE2 interaction is a crucial step to mediate the host cell entry of SARS-CoV-2. Recent studies indicate that the ACE2 interaction with the SARS-CoV-2 S protein has a higher affinity than its binding with the structurally identical S protein of SARS-CoV-1, the virus causing the 2002-2004 SARS outbreak. However, the biophysical mechanism behind such binding affinity difference is unclear. This study utilizes combined single-molecule force spectroscopy and steered molecular dynamics (SMD) simulation approaches to quantify the specific interactions between SARS-CoV-2 or SARS-CoV-1 RBD and ACE2. Depending on the loading rates, the unbinding forces between SARS-CoV-2 RBD and ACE2 range from 70 to 105 pN and are 30-40% higher than those of SARS-CoV-1 RBD and ACE2 under similar loading rates. SMD results indicate that SARS-CoV-2 RBD interacts with the N-linked glycan on Asn90 of ACE2. This interaction is mostly absent in the SARS-CoV-1 RBD-ACE2 complex. During the SMD simulations, the extra RBD-N-glycan interaction contributes to a greater force and prolonged interaction lifetime. The observation is confirmed by our experimental force spectroscopy study. After removing N-linked glycans on ACE2, its mechanical binding strength with SARS-CoV-2 RBD decreases to a similar level of the SARS-CoV-1 RBD-ACE2 interaction. Together, the study uncovers the mechanism behind the difference in ACE2 binding between SARS-CoV-2 and SARS-CoV-1 and could help develop new strategies to block SARS-CoV-2 entry.

Indexed as

Angiotensin-Converting Enzyme 2Biomechanical PhenomenaComputer SimulationHEK293 CellsHumansModels, BiologicalPolysaccharidesProtein BindingProtein DomainsSingle Molecule ImagingSpike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2PolysaccharidesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID33607086
PMCPMC7886630
OpenAlexW3130583627

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.